Should Infliximab be Used as an Adjuvant to IVIG in the Treatment of Children With Kawasaki Disease Who Are at High Risk for Resistance to Conventional Therapy?

被引：0

作者：

Shelby Davies

Gabrielle Gold-von Simson

机构：

[1] New York University School of Medicine,

来源：

Pediatric Cardiology | 2013年 / 34卷

关键词：

Vasculitis; Infliximab; Kawasaki Disease; Artery Aneurysm; IVIG Therapy;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1756 / 1756

共 27 条

[21] Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial
Martin, Miguel
Hegg, Roberto
Kim, Sung-Bae
Schenker, Michael
Grecea, Daniela
Angel Garcia-Saenz, Jose
Papazisis, Konstantinos
Ouyang, Quchang
Lacko, Aleksandra
Oksuzoglu, Berna
Reeves, James
Okera, Meena
Testa, Laura
Shimizu, Chikako
Denduluri, Neelima
Adamchuk, Hryhoriy
Dakhil, Shaker
Wei, Ran
Forrester, Tammy
Fernandez, Maria Munoz
Zimmermann, Annamaria
Headley, Desiree
Johnston, Stephen R. D.
JAMA ONCOLOGY, 2022, 8 (08) : 1190 - 1194
[22] Impact of chronic kidney disease on oncological outcomes in patients with high-risk non-muscle-invasive bladder cancer who underwent adjuvant bacillus Calmette-Guerin therapy
Fujita, Naoki
Hatakeyama, Shingo
Okita, Kazutaka
Momota, Masaki
Narita, Takuma
Tobisawa, Yuki
Yoneyama, Tohru
Yamamoto, Hayato
Imai, Atsushi
Ito, Hiroyuki
Yoneyama, Takahiro
Hashimoto, Yasuhiro
Yoshikawa, Kazuaki
Ohyama, Chikara
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (03) : 191.e9 - 191.e16
[23] Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
Furuhashi, Masato
Sakuma, Ichiro
Morimoto, Takeshi
Higashiura, Yukimura
Sakai, Akiko
Matsumoto, Megumi
Sakuma, Mio
Shimabukuro, Michio
Nomiyama, Takashi
Arasaki, Osamu
Node, Koichi
Ueda, Shinichiro
CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
[24] Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
Masato Furuhashi
Ichiro Sakuma
Takeshi Morimoto
Yukimura Higashiura
Akiko Sakai
Megumi Matsumoto
Mio Sakuma
Michio Shimabukuro
Takashi Nomiyama
Osamu Arasaki
Koichi Node
Shinichiro Ueda
Cardiovascular Diabetology, 19
[25] A Phase 3 Randomized, Double Blind, Placebo-Controlled Multicenter Study Comparing Denosumab with Placebo as Adjuvant Treatment for Women with Early-Stage Breast Cancer Who Are at High Risk of Disease Recurrence (D-CARE).
Goss, P. E.
Barrios, C. H.
Bell, R.
Finkelstein, D.
Iwata, H.
Martin, M.
Braun, A.
Ke, C.
Maniar, T.
Braun, S.
Dansey, R.
Coleman, R. E.
CANCER RESEARCH, 2011, 71
[26] A randomized, double-blind, placebo-controlled multicenter phase III study comparing denosumab with placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE).
Goss, P. E.
Barrios, C. H.
Bell, R.
Finkelstein, D.
Iwata, H.
Martin, M.
Braun, A. H.
Dansey, R. D.
Coleman, R. E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[27] Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.
Goss, Paul Edward
Barrios, Carlos H.
Bell, Richard
Finkelstein, Dianne M.
Iwata, Hiroji
Martin, Miguel
Braun, Ada H.
Ke, Chunlei
Maniar, Tapan
Coleman, Robert Edward
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 →